Innate Pharma (IPHA) Retained Earnings (2017 - 2025)

Innate Pharma (IPHA) has reported Retained Earnings for 9 consecutive years, with -$439.7 million the latest figure, recorded in Q4 2025.

• Quarterly Retained Earnings fell 14.68% year-over-year to -$439.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$439.7 million (down 14.68% YoY) and the FY2025 annual result came in at -$439.7 million, down 14.68% from the prior year.
• Retained Earnings fell to -$439.7 million in Q4 2025 per IPHA's latest filing, from $1.4 million in the prior quarter.
• Over the last five years, Retained Earnings for IPHA reached as high as $1.4 million in Q2 2025 and fell as low as -$439.7 million in Q4 2025.
• A 5-year average of -$119.2 million and a median of $460871.5 in 2021 frame the typical range for Retained Earnings.
• The largest YoY upside for Retained Earnings was 274.65% in 2023 against a maximum downside of 40310.38% in 2023.
• Year by year, Retained Earnings stood at $518907.1 in 2021, then jumped by 79.61% to $931984.5 in 2022, then tumbled by 40310.38% to -$374.8 million in 2023, then retreated by 2.3% to -$383.4 million in 2024, then retreated by 14.68% to -$439.7 million in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered -$439.7 million, $1.4 million, and -$383.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.